ClinicalTrials.gg
CompletedNCT02696785COAST-VUpdated Nov 19, 2019Results posted

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Spondylarthritis with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · United States.

Enrollment
7th of 14
341 · median 329
Started
2016
with 2 others
Phase 3
7 of 27
none open now
Registered
14th of 27
by date
Lead sponsor
3 of 27
Eli Lilly and Company

Among the 27 studies in Spondylarthritis with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 14th registered.

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

Browse Spondylarthritis studies →

Open to participants now

6 of the 27 studies in Spondylarthritis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Spondylarthritis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).

03

Conditions studied

  • Spondyloarthritis

Keywords

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ambulatory.
  • Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.
  • Participants have a history of back pain ≥3 months with age at onset \<45 years.
  • In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (for duration 4 weeks) or cannot tolerate NSAIDS.
  • If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.
  • Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have total ankylosis of the spine.
  • Have received any prior, or are currently receiving, treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents.
  • Have recently received a within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.
  • Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.
  • Have a compromised immune system.
  • Have any other serious and/or uncontrolled diseases.
  • Have either a current diagnosis or a recent history of malignant disease.
  • Have had major surgery within 8 weeks of baseline, or will require surgery during the study.
  • Are pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    Q2W Ixekizumab

    Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.

    Drug: Ixekizumab

  • Experimental
    Q4W Ixekizumab

    Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Double Blind Period: Placebo given SC Q2W to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.

    Drug: Ixekizumab · Drug: Placebo

  • Active comparator
    Adalimumab

    Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52.

    Drug: Ixekizumab · Drug: Adalimumab

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

  • Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

    ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving an ASAS20 Response

    ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

  2. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  3. Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem). BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

    Time frame: Week 16

  4. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  5. Percentage of Participants Achieving ASDAS Inactive Disease

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of \<1.3.

    Time frame: Week 16

  6. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)

    The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease. Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  7. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  8. Change From Baseline in ASAS Health Index (ASAS HI)

    ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors

    Time frame: Baseline, Week 16

  9. Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

    High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)

    The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA. 1. Lateral spinal flexion 2. Tragus-to-wall distance 3. Lumbar flexion (modified Schrober) 4. Maximal intermalleolar distance 5. Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Chest Expansion

    While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  12. Change From Baseline in Occiput to Wall Distance

    The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  13. Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

    Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  14. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  15. Change From Baseline in SPARCC Enthesitis Score

    The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  16. Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)

    The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  17. Number of Participants With Anterior Uveitis or Uveitis Flares

    Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Baseline through Week 16

  18. Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

    The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  19. Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

    The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = "no days" to 5 = "22-30 days." The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  20. Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

    The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  21. Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

    ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.

    Time frame: Baseline, Week 52

  22. Number of Participants With Anti Ixekizumab Antibodies

    A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10.

    Time frame: Week 16

  23. Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)

    Time frame: Week 16

  24. Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)

    The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. "sum of all joints checked to be swollen" divided by "number of evaluable joints" and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  25. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

    MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors

    Time frame: Baseline, Week 16

07

Results

Posted Nov 19, 2019

Participant flow

Blinded treatment period (Week 0 to Week 16), followed by extended treatment period (Week 16 to Week 52), followed by post treatment period for a maximum of 24 weeks. Washout period occurred for only Adalimumab group for 6 weeks (Week 14 to Week 20).

Blinded Treatment Period
Participant flow — Blinded Treatment Period
MilestonePBO/IXEADA/PBO/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4W
Started87908381
Received at least one dose of study drug86908381
Completed86887978
Not completed1243
Withdrew: Adverse event0130
Withdrew: Withdrawal by subject0112
Withdrew: Lack of efficacy0001
Withdrew: Screen failure1000
Washout Period
Participant flow — Washout Period
MilestonePBO/IXEADA/PBO/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4W
Started08800
Completed08600
Not completed0200
Withdrew: Withdrawal by subject0100
Withdrew: Lack of efficacy0100
Extended Treatment Period
Participant flow — Extended Treatment Period
MilestonePBO/IXEADA/PBO/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4W
Started86867978
Completed83807472
Not completed3656
Withdrew: Adverse event2321
Withdrew: Lack of efficacy0100
Withdrew: Withdrawal by subject1235
Follow-up Period
Participant flow — Follow-up Period
MilestonePBO/IXEADA/PBO/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4W
Started102416
Completed00118
Not completed10138
Withdrew: Adverse event0082
Withdrew: Lost to follow-up0001
Withdrew: Lack of efficacy0001
Withdrew: Withdrawal by subject1054

Outcome measures

PrimaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
percentage of participantsPlaceboAdalimumabIXE80Q4WIXE80Q2W
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response18.435.648.151.8
Statistical analysis
  • Placebo vs Adalimumab · Regression, Logistic · p = 0.005 · Odds ratio (or): 2.73 · 95% CI 1.35 to 5.52
  • Placebo vs IXE80Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.45 · 95% CI 2.20 to 9.03
  • Placebo vs IXE80Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.09 · 95% CI 2.52 to 10.28
  • Placebo vs Adalimumab · ANCOVA · p = <0.001 · Lsmean difference: -7.0 · 95% CI -13.2 to -0.7
  • Placebo vs IXE80Q2W · ANCOVA · p = <0.001 · Lsmean difference: -9.3 · 95% CI -15.5 to -3.0
  • Placebo vs IXE80Q4W · ANCOVA · p = <0.001 · Lsmean difference: -8.9 · 95% CI -15.2 to -2.5
SecondaryPercentage of Participants Achieving an ASAS20 Response

ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ASAS20 Response
percentage of participantsPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Percentage of Participants Achieving an ASAS20 Response40.258.964.268.7
Statistical analysis
  • Placebo vs Adalimumab 40mg · Regression, Logistic · p = 0.007 · Odds ratio (or): 2.30 · 95% CI 1.25 to 4.23
  • Placebo vs IXE80Q4W · Regression, Logistic · p = 0.001 · Odds ratio (or): 2.78 · 95% CI 1.48 to 5.24
  • Placebo vs IXE80Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.39 · 95% CI 1.79 to 6.41
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.46 ± 0.099-1.30 ± 0.096-1.43 ± 0.102-1.37 ± 0.101
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.84 · 95% CI -1.11 to -0.57
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.97 · 95% CI -1.25 to -0.70
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.91 · 95% CI -1.18 to -0.63
SecondaryPercentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem). BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
percentage of participantsPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response17.232.242.043.4
Statistical analysis
  • Placebo vs Adalimumab 40mg · Regression, Logistic · p = 0.012 · Odds ratio (or): 2.53 · 95% CI 1.23 to 5.21
  • Placebo vs IXE80Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.74 · 95% CI 1.82 to 7.70
  • Placebo vs IXE80Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.90 · 95% CI 1.91 to 7.98
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)-1.16 ± 0.215-2.14 ± 0.209-2.39 ± 0.222-2.43 ± 0.219
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.001 · Lsmean difference: -0.97 · 95% CI -1.56 to -0.39
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.22 · 95% CI -1.83 to -0.62
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.27 · 95% CI -1.86 to -0.67
SecondaryPercentage of Participants Achieving ASDAS Inactive Disease

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of \<1.3.

Time frame:
Week 16
Reported as:
Number · percentage of Participants
Percentage of Participants Achieving ASDAS Inactive Disease
percentage of ParticipantsPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Percentage of Participants Achieving ASDAS Inactive Disease2.315.616.010.8
Statistical analysis
  • Placebo vs Adalimumab 40mg · Regression, Logistic · p = 0.009 · Lsmean difference: 7.62 · 95% CI 1.67 to 34.68
  • Placebo vs IXE80Q4W · Regression, Logistic · p = 0.007 · Odds ratio (or): 8.03 · 95% CI 1.75 to 36.83
  • Placebo vs IXE80Q2W · Regression, Logistic · p = 0.041 · Odds ratio (or): 5.13 · 95% CI 1.07 to 24.49
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)

The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease. Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)-0.15 ± 0.323-2.92 ± 0.314-2.77 ± 0.328-2.54 ± 0.330
Statistical analysis
  • Placebo vs Adalimumab 40mg · ANCOVA · p = <0.001 · Lsmean difference: -2.78 · 95% CI -3.7 to -1.9
  • Placebo vs IXE80Q4W · ANCOVA · p = <0.001 · Lsmean difference: -2.62 · 95% CI -3.5 to -1.7
  • Placebo vs IXE80Q2W · ANCOVA · p = <0.001 · Lsmean difference: -2.39 · 95% CI -3.3 to -1.5
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
PCS3.6432 ± 0.75306.9005 ± 0.73107.6952 ± 0.77687.9686 ± 0.7665
MCS2.1229 ± 0.84312.5550 ± 0.82252.7502 ± 0.87632.5696 ± 0.8650
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.002 · Lsmean difference: 3.2574 · 95% CI 1.2041 to 5.3106
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 4.0520 · 95% CI 1.9432 to 6.1608
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 4.3254 · 95% CI 2.2321 to 6.4186
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.713 · Lsmean difference: 0.4321 · 95% CI -1.8732 to 2.7373
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.602 · Lsmean difference: 0.6273 · 95% CI -1.7387 to 2.9934
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.709 · Lsmean difference: 0.4467 · 95% CI -1.9097 to 2.8030
SecondaryChange From Baseline in ASAS Health Index (ASAS HI)

ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in ASAS Health Index (ASAS HI)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in ASAS Health Index (ASAS HI)-1.25 ± 0.300-2.30 ± 0.292-2.36 ± 0.311-2.74 ± 0.306
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.012 · Lsmean difference: -1.05 · 95% CI -1.87 to -0.23
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.010 · Lsmean difference: -1.11 · 95% CI -1.95 to -0.27
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.49 · 95% CI -2.32 to -0.66
SecondaryChange From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Milliragm per Litre (mg/mL)
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
Milliragm per Litre (mg/mL)PlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)1.426 ± 1.9244-7.202 ± 1.8688-5.209 ± 1.9803-6.565 ± 1.9582
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.001 · Lsmean difference: -8.628 · 95% CI -13.885 to -3.371
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.016 · Lsmean difference: -6.635 · 95% CI -12.033 to -1.238
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.004 · Lsmean difference: -7.991 · 95% CI -13.351 to -2.631
SecondaryChange From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)

The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA. 1. Lateral spinal flexion 2. Tragus-to-wall distance 3. Lumbar flexion (modified Schrober) 4. Maximal intermalleolar distance 5. Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)-0.080 ± 0.0826-0.447 ± 0.0800-0.502 ± 0.0858-0.408 ± 0.0840
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.001 · Lsmean difference: -0.367 · 95% CI -0.592 to -0.142
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.422 · 95% CI -0.655 to -0.189
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.005 · Lsmean difference: -0.329 · 95% CI -0.558 to -0.099
SecondaryChange From Baseline in Chest Expansion

While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Centimeters (cm)
Change From Baseline in Chest Expansion
Centimeters (cm)PlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Chest Expansion0.06 ± 0.1520.70 ± 0.1480.49 ± 0.1580.67 ± 0.155
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.003 · Lsmean difference: 0.63 · 95% CI 0.22 to 1.05
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.051 · Lsmean difference: 0.43 · 95% CI -0.00 to 0.86
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.005 · Lsmean difference: 0.60 · 95% CI 0.18 to 1.03
SecondaryChange From Baseline in Occiput to Wall Distance

The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · cm
Change From Baseline in Occiput to Wall Distance
cmPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Occiput to Wall Distance-0.06 ± 0.232-0.72 ± 0.225-0.69 ± 0.240-0.73 ± 0.236
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.039 · Lsmean difference: -0.67 · 95% CI -1.30 to -0.03
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.057 · Lsmean difference: -0.63 · 95% CI -1.28 to 0.02
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.042 · Lsmean difference: -0.67 · 95% CI -1.31 to -0.03
SecondaryChange From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score0.92 ± 0.582-4.21 ± 0.568-3.97 ± 0.590-4.25 ± 0.591
Statistical analysis
  • Placebo vs Adalimumab 40mg · ANCOVA · p = <0.001 · Lsmean difference: -5.13 · 95% CI -6.7 to -3.5
  • Placebo vs IXE80Q4W · ANCOVA · p = <0.001 · Lsmean difference: -4.89 · 95% CI -6.5 to -3.3
  • Placebo vs IXE80Q2W · ANCOVA · p = <0.001 · Lsmean difference: -5.17 · 95% CI -6.8 to -3.6
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)-2.1 ± 0.34-2.6 ± 0.34-2.3 ± 0.36-2.4 ± 0.35
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.317 · Lsmean difference: -0.5 · 95% CI -1.4 to 0.5
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.683 · Lsmean difference: -0.2 · 95% CI -1.1 to 0.8
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.500 · Lsmean difference: -0.3 · 95% CI -1.3 to 0.6
SecondaryChange From Baseline in SPARCC Enthesitis Score

The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in SPARCC Enthesitis Score
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in SPARCC Enthesitis Score-2.1 ± 0.40-2.9 ± 0.40-2.7 ± 0.40-2.6 ± 0.43
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.154 · Lsmean difference: -0.8 · 95% CI -1.9 to 0.3
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = -0.6 · Lsmean difference: 0.255 · 95% CI -1.8 to 0.5
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.398 · Lsmean difference: -0.5 · 95% CI -1.6 to 0.7
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Tender (TJC)

The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)-2.0 ± 0.53-2.2 ± 0.55-2.5 ± 0.58-3.3 ± 0.58
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.783 · Lsmean difference: -0.2 · 95% CI -1.7 to 1.3
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.550 · Lsmean difference: -0.5 · 95% CI -2.0 to 1.1
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.091 · Lsmean difference: -1.3 · 95% CI -2.8 to 0.2
SecondaryNumber of Participants With Anterior Uveitis or Uveitis Flares

Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Baseline through Week 16
Reported as:
Number · Count of Participants
Number of Participants With Anterior Uveitis or Uveitis Flares
Count of ParticipantsPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Number of Participants With Anterior Uveitis or Uveitis Flares0010
SecondaryChange From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score-1.4 ± 0.23-2.2 ± 0.23-2.5 ± 0.24-2.1 ± 0.24
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.027 · Lsmean difference: -0.7 · 95% CI -1.3 to -0.1
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.002 · Lsmean difference: -1.0 · 95% CI -1.7 to -0.4
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.035 · Lsmean difference: -0.7 · 95% CI -1.3 to -0.0
SecondaryChange From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = "no days" to 5 = "22-30 days." The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)-1.5 ± 0.41-2.7 ± 0.40-2.5 ± 0.43-3.0 ± 0.42
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.041 · Lsmean difference: -1.2 · 95% CI -2.3 to -0.0
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.125 · Lsmean difference: -0.9 · 95% CI -2.1 to 0.3
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.013 · Lsmean difference: -1.4 · 95% CI -2.6 to -0.3
SecondaryChange From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Overall Work Impairment Score-17.82 ± 3.254-21.44 ± 2.921-21.36 ± 3.061-24.06 ± 3.299
Percentage of Activity Impairment-14.1 ± 2.28-21.1 ± 2.22-23.0 ± 2.35-23.4 ± 2.30
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.989 · Lsmean difference: 0.04 · 95% CI -6.03 to 6.12
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.429 · Lsmean difference: 2.50 · 95% CI -3.71 to 8.70
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.096 · Lsmean difference: -5.47 · 95% CI -11.92 to 0.98
SecondaryChange From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
score on a scalePlacebo/IxekizumabAdalimumab/IxekizumabIxekizumab Q4W/Ixekizumab Q4WIxekizumab 80mg Q2W/Ixekizumab 80mg Q2W
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score-10.28 ± 27.472-5.91 ± 20.861-7.62 ± 25.430-9.91 ± 27.940
SecondaryNumber of Participants With Anti Ixekizumab Antibodies

A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Anti Ixekizumab Antibodies
ParticipantsPlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Number of Participants With Anti Ixekizumab Antibodies2522
SecondaryPharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Time frame:
Week 16
Reported as:
Geometric mean · microgram per millilitre (μg/mL)
Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)
microgram per millilitre (μg/mL)IXE80Q4WIXE160/80Q4WIXE80Q2WIXE160/80Q2W
Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)3.56 ± 563.88 ± 5511.6 ± 5411.3 ± 43
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)

The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. "sum of all joints checked to be swollen" divided by "number of evaluable joints" and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)
score on a scalePlaceboAdalimumab 40mgIXE80Q4WIXE80Q2W
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)-1.7 ± 0.55-2.7 ± 0.53-3.6 ± 0.53-2.7 ± 0.57
Statistical analysis
  • Placebo vs Adalimumab 40mg · Mixed Models Analysis · p = 0.166 · Lsmean difference: -1.1 · 95% CI -2.6 to 0.4
  • Placebo vs IXE80Q4W · Mixed Models Analysis · p = 0.011 · Lsmean difference: -1.9 · 95% CI -3.4 to -0.4
  • Placebo vs IXE80Q2W · Mixed Models Analysis · p = 0.182 · Lsmean difference: -1.0 · 95% CI -2.6 to 0.5
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
score on a scalePlaceboAdalimumabIXE80Q4WIXE80Q2W
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)-1.51 ± 1.147-11.57 ± 1.113-11.02 ± 1.160-9.58 ± 1.168
Statistical analysis
  • Placebo vs Adalimumab · ANCOVA · p = <0.001 · Lsmean difference: -10.07 · 95% CI -13.2 to -6.9
  • Placebo vs IXE80Q4W · ANCOVA · p = <0.001 · Lsmean difference: -9.51 · 95% CI -12.6 to -6.4
  • Placebo vs IXE80Q2W · ANCOVA · p = <0.001 · Lsmean difference: -8.08 · 95% CI -11.2 to -4.9

Adverse events

Collected over Upto 76 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Blinded Treatment0/86 (0%)0/86 (0%)12/86 (14%)
Adalimumab 40mg - Blinded Treatment0/90 (0%)3/90 (3.3%)16/90 (17.8%)
IXE80Q2W - Blinded Treatment0/83 (0%)1/83 (1.2%)18/83 (21.7%)
IXE80Q4W - Blinded Treatment0/81 (0%)1/81 (1.2%)11/81 (13.6%)
ADA/PBO - Washout Treatment Period0/88 (0%)0/88 (0%)8/88 (9.1%)
PBO/IXE - Extended Treatment Period0/86 (0%)4/86 (4.7%)26/86 (30.2%)
ADA/PBO/IXE - Extended Treatment Period0/86 (0%)7/86 (8.1%)20/86 (23.3%)
IXE80Q2W/IXE80Q2W - Extended Treatment0/79 (0%)3/79 (3.8%)21/79 (26.6%)
IXE80Q4W/IXE80Q4W - Extended Treatment0/78 (0%)4/78 (5.1%)14/78 (17.9%)
PBO-follow-up Period0/1 (0%)0/1 (0%)1/1 (100%)
IXE80Q2W-follow-up Period0/24 (0%)0/24 (0%)2/24 (8.3%)
IXE80Q4W-follow-up Period0/16 (0%)0/16 (0%)2/16 (12.5%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlacebo - Blinded TreatmentAdalimumab 40mg - Blinded TreatmentIXE80Q2W - Blinded TreatmentIXE80Q4W - Blinded TreatmentADA/PBO - Washout Treatment PeriodPBO/IXE - Extended Treatment PeriodADA/PBO/IXE - Extended Treatment PeriodIXE80Q2W/IXE80Q2W - Extended TreatmentIXE80Q4W/IXE80Q4W - Extended TreatmentPBO-follow-up PeriodIXE80Q2W-follow-up PeriodIXE80Q4W-follow-up Period
Adnexal torsionReproductive system and breast disorders0/151/170/190/130/170/150/160/180/130/10/90/3
Radius fractureInjury, poisoning and procedural complications0/860/900/830/810/880/860/860/791/780/10/240/16
Road traffic accidentInjury, poisoning and procedural complications0/860/900/830/810/880/860/860/791/780/10/240/16
Blood creatine phosphokinase increasedInvestigations0/860/900/830/810/880/860/860/791/780/10/240/16
ArthritisMusculoskeletal and connective tissue disorders0/860/900/830/810/880/860/860/791/780/10/240/16
TonsillitisInfections and infestations0/860/900/830/810/880/860/861/790/780/10/240/16
Avulsion fractureInjury, poisoning and procedural complications0/860/900/830/810/880/860/861/790/780/10/240/16
Plica syndromeMusculoskeletal and connective tissue disorders0/860/900/830/810/880/860/861/790/780/10/240/16
Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/860/900/830/810/880/860/861/790/780/10/240/16
Urinary tract infectionInfections and infestations0/860/900/831/810/880/860/860/790/780/10/240/16
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo - Blinded TreatmentAdalimumab 40mg - Blinded TreatmentIXE80Q2W - Blinded TreatmentIXE80Q4W - Blinded TreatmentADA/PBO - Washout Treatment PeriodPBO/IXE - Extended Treatment PeriodADA/PBO/IXE - Extended Treatment PeriodIXE80Q2W/IXE80Q2W - Extended TreatmentIXE80Q4W/IXE80Q4W - Extended TreatmentPBO-follow-up PeriodIXE80Q2W-follow-up PeriodIXE80Q4W-follow-up Period
Ocular discomfortEye disorders0/860/900/830/810/880/860/860/790/781/10/240/16
Menopausal symptomsReproductive system and breast disorders0/150/170/190/130/170/150/160/180/131/10/90/3
NasopharyngitisInfections and infestations6/866/905/836/816/8817/867/867/798/780/10/240/16
Back painMusculoskeletal and connective tissue disorders1/861/901/830/810/880/861/861/793/780/10/242/16
Upper respiratory tract infectionInfections and infestations4/862/904/837/812/884/864/868/794/780/11/240/16
Injection site reactionGeneral disorders2/863/907/830/810/888/868/866/793/780/10/240/16
Menstruation irregularReproductive system and breast disorders1/150/170/190/130/170/150/160/180/130/10/90/3
Vaginal infectionInfections and infestations0/151/170/190/130/170/150/160/180/130/10/90/3
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/170/190/130/170/150/160/180/130/10/90/3
Adnexal torsionReproductive system and breast disorders0/151/170/190/130/170/150/160/180/130/10/90/3

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PBO/IXEADA/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4WTotal
Mean42.7 ± 12.0141.8 ± 11.4441.3 ± 11.1741.0 ± 12.1341.7 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)PBO/IXEADA/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4WTotal
Female1517191364
Male71736468276
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PBO/IXEADA/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4WTotal
Hispanic or Latino1178834
Not Hispanic or Latino67746866275
Unknown or Not Reported897731
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PBO/IXEADA/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4WTotal
American Indian or Alaska Native424414
Asian28292525107
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White52575252213
More than one race22206
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)PBO/IXEADA/IXEIXE80Q2W/IXE80Q2WIXE80Q4W/IXE80Q4WTotal
South Korea1014121147
Netherlands02204
United States534315
Czechia1414131354
Japan33017
Taiwan1312131351
Germany02103
Canada23229
Hungary322310
Mexico878730
Poland1615151662
Russia1213111248
08

Study locations

28 sites
  • Arizona Arthritis Research, PLC
    Phoenix, Arizona 85032, United States
  • Care Access Research - Huntington Beach
    Huntington Beach, California 92648, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
    Colorado Springs, Colorado 80920, United States
  • Denver Arthritis Center
    Denver, Colorado 80230, United States
  • New England Research Associates
    Trumbull, Connecticut 06611, United States
  • Sarasota Arthritis Center
    Sarasota, Florida 34239, United States
  • Marietta Rheumatology
    Marietta, Georgia 30060, United States
  • Center for Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland 21740, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Shanahan Rheumatology & Immunotherapy
    Raleigh, North Carolina 27617, United States
  • Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
    Columbia, South Carolina 29204, United States
  • Low Country Research Center
    North Charleston, South Carolina 29406, United States
  • Univ of Texas Health Science Center - Houston
    Houston, Texas 77030, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brno, 611 41, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 12203, Germany
  • "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Hyōgo, 366 8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gwangjin-gu, 05080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 04763, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 02-691, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung City, 40201, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40447, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 10048, Taiwan
09

References and documents

Publications

  • van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther. 2022 Jun;39(6):2806-2819. doi: 10.1007/s12325-022-02132-2. Epub 2022 Apr 16. PubMed 35429281 ↗
  • Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, Ostergaard M, Tada K, Baraliakos X, Deodhar A, Gensler LS. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022 Nov 2;61(11):4324-4334. doi: 10.1093/rheumatology/keac104. PubMed 35188180 ↗
  • van der Heijde D, Ostergaard M, Reveille JD, Baraliakos X, Kronbergs A, Sandoval DM, Li X, Carlier H, Adams DH, Maksymowych WP. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. J Rheumatol. 2022 Mar;49(3):265-273. doi: 10.3899/jrheum.210471. Epub 2021 Dec 1. PubMed 34853086 ↗
  • Deodhar AA, Mease PJ, Rahman P, Navarro-Compan V, Strand V, Hunter T, Bolce R, Leon L, Lauzon S, Marzo-Ortega H. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021 Sep 20;5(1):35. doi: 10.1186/s41927-021-00205-3. PubMed 34538257 ↗
  • Dougados M, Wei JC, Landewe R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4. Erratum In: Ann Rheum Dis. 2020 Jun;79(6):e75. doi: 10.1136/annrheumdis-2019-216118corr1. PubMed 31685553 ↗
  • Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28. PubMed 31254223 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Dec 2017, 19 months.

Results were first posted in Nov 2019, 1 year 11 months after primary completion. A results delay was requested in Jun 2018.

Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2016
First posted
Mar 2, 2016
StartActual
May 2, 2016
Primary completionActual
Dec 8, 2017
CompletionActual
Oct 17, 2018
Results delay requested
Jun 4, 2018
Results first posted
Nov 19, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02696785
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
May 2, 2016
Primary completion
Dec 8, 2017
Completion
Oct 17, 2018
Results posted
Nov 19, 2019
Last update
Nov 19, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion